Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-701 in healthy participants
NCT07396909Phase 1Completed
- Start
- Jan 2026
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MT-701 (2 arms). Primary endpoint: Number of Subjects with non-SAEs and SAES at 14 days. Started Jan 2026; status: completed.
02
Drugs
MT-701
Beyond the preview
Go deeper on NCT07396909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07396909.